High tumor telomerase activity is a well-established negative prognostic factor across multiple cancer indications [20–24], whereas anti-telomerase CD4 T cell immune responses are emerging as independent positive prognostic factors validated in several malignancies [25–27]. This evidence concerns the gene CD4 and neoplasm.